CHA Vaccine Research Institute (KOSDAQ:261780)
South Korea
· Delayed Price · Currency is KRW 3,985.00
+125.00 (3.24%)
At close: Apr 28, 2026
KOSDAQ:261780 Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Cash & Equivalents | 9,775 | 10,092 | 5,906 | 2,386 | 3,955 | Upgrade
|
| Short-Term Investments | 13,490 | 22,550 | 32,990 | 55,377 | 47,500 | Upgrade
|
| Trading Asset Securities | 406.79 | 7,465 | - | - | 10,095 | Upgrade
|
| Cash & Short-Term Investments | 23,672 | 40,107 | 38,896 | 57,763 | 61,550 | Upgrade
|
| Cash Growth | -40.98% | 3.11% | -32.66% | -6.15% | 147.92% | Upgrade
|
| Accounts Receivable | -0 | -0 | 0 | -0 | -0 | Upgrade
|
| Other Receivables | 468.61 | 399.87 | 453.87 | 607.81 | 266.9 | Upgrade
|
| Receivables | 468.61 | 399.87 | 453.87 | 607.8 | 266.9 | Upgrade
|
| Prepaid Expenses | 77.23 | 106.63 | 94.23 | 117.1 | 12.94 | Upgrade
|
| Other Current Assets | 2,661 | 3,977 | 3,042 | 429 | 17.07 | Upgrade
|
| Total Current Assets | 26,879 | 44,590 | 42,486 | 58,917 | 61,847 | Upgrade
|
| Property, Plant & Equipment | 842.79 | 1,120 | 1,644 | 1,543 | 1,032 | Upgrade
|
| Long-Term Investments | 1,612 | 1,069 | 674.6 | 440 | 2,300 | Upgrade
|
| Other Intangible Assets | 229.85 | 174.67 | 43.58 | 39.91 | 21.77 | Upgrade
|
| Long-Term Accounts Receivable | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Other Long-Term Assets | 217.88 | 294.39 | 270.9 | 129.08 | 112.5 | Upgrade
|
| Total Assets | 29,782 | 47,248 | 45,119 | 61,069 | 65,313 | Upgrade
|
| Accrued Expenses | 105.37 | 129.31 | 146.74 | 77.43 | 60.77 | Upgrade
|
| Short-Term Debt | 8,841 | 4,950 | - | 23,240 | 20,717 | Upgrade
|
| Current Portion of Leases | - | 8.35 | 162.92 | 381.21 | 112.8 | Upgrade
|
| Other Current Liabilities | 7,239 | 4,526 | 500.53 | 3,090 | 3,816 | Upgrade
|
| Total Current Liabilities | 16,185 | 9,613 | 810.18 | 26,789 | 24,706 | Upgrade
|
| Long-Term Debt | - | 4,627 | 3,975 | - | - | Upgrade
|
| Long-Term Leases | - | 3.81 | 188.65 | 16.53 | 16.14 | Upgrade
|
| Pension & Post-Retirement Benefits | 1,625 | 1,620 | 1,203 | 882.35 | 737.9 | Upgrade
|
| Other Long-Term Liabilities | 112.64 | 3,662 | 3,525 | 15.09 | 237.52 | Upgrade
|
| Total Liabilities | 17,923 | 19,526 | 9,702 | 27,703 | 25,698 | Upgrade
|
| Common Stock | 13,433 | 13,412 | 13,366 | 13,215 | 13,215 | Upgrade
|
| Additional Paid-In Capital | 79,870 | 79,687 | 76,782 | 72,576 | 72,576 | Upgrade
|
| Retained Earnings | -81,939 | -65,920 | -55,457 | -53,615 | -46,921 | Upgrade
|
| Comprehensive Income & Other | 495.63 | 542.97 | 725.68 | 1,190 | 745.6 | Upgrade
|
| Shareholders' Equity | 11,859 | 27,722 | 35,417 | 33,366 | 39,615 | Upgrade
|
| Total Liabilities & Equity | 29,782 | 47,248 | 45,119 | 61,069 | 65,313 | Upgrade
|
| Total Debt | 8,841 | 9,589 | 4,327 | 23,638 | 20,846 | Upgrade
|
| Net Cash (Debt) | 14,831 | 30,518 | 34,569 | 34,125 | 40,704 | Upgrade
|
| Net Cash Growth | -51.40% | -11.72% | 1.30% | -16.16% | 579.94% | Upgrade
|
| Net Cash Per Share | 551.84 | 1137.84 | 1298.66 | 1290.78 | 1745.71 | Upgrade
|
| Filing Date Shares Outstanding | 26.95 | 26.82 | 26.73 | 26.43 | 26.43 | Upgrade
|
| Total Common Shares Outstanding | 26.95 | 26.82 | 26.73 | 26.43 | 26.43 | Upgrade
|
| Working Capital | 10,694 | 34,977 | 41,676 | 32,128 | 37,141 | Upgrade
|
| Book Value Per Share | 440.12 | 1033.46 | 1324.89 | 1262.45 | 1498.91 | Upgrade
|
| Tangible Book Value | 11,629 | 27,548 | 35,373 | 33,326 | 39,593 | Upgrade
|
| Tangible Book Value Per Share | 431.59 | 1026.95 | 1323.26 | 1260.94 | 1498.09 | Upgrade
|
| Land | 95.09 | 95.09 | 95.09 | 95.09 | 95.09 | Upgrade
|
| Buildings | 402.68 | 402.68 | 402.68 | 402.68 | 402.68 | Upgrade
|
| Machinery | 2,205 | 2,086 | 1,933 | 1,622 | 1,079 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.